Please login to the form below

Not currently logged in
Email:
Password:

FDA reveals restricted use of Novartis' Zelnorm

The FDA permits the restricted use of constipation-predominant IBS drug Zelnorm under a treatment investigational new drug protocol

The FDA has permitted the restricted use of constipation-predominant IBS drug Zelnorm (tegaserod) under a treatment investigational new drug protocol.

The ruling also includes the treatment of chronic idiopathic constipation (CIC) in women younger under 55 years of age who meet specific guidelines. Zelnorm will remain off the market for general use.

Patients with a serious or life-threatening disease or condition who are not enrolled in a clinical trial may be treated with a drug not approved by the FDA. Such use is allowed within guidelines called a treatment IND, when no comparable or satisfactory alternative drug or therapy is available. These patients must meet strict criteria and have no known or pre-existing heart problems and be in critical need of this drug.

In FY06, Zelnorm sales were USD 561m, of which US sales accounted for USD 488m. Novartis revised its FY07 local currency sales growth outlook as a result and said it expected sales to grow above five percent. The company continues to stress that no causal relationship exists between ischemic CV events and tegaserod.

30th July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics